{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:09:16Z","timestamp":1779883756014,"version":"3.53.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12325-021-01982-6","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T07:02:31Z","timestamp":1637564551000},"page":"562-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Kari","family":"Kelton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Belger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"McCollam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Spiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-6400","authenticated-orcid":false,"given":"Russel","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"issue":"8","key":"1982_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333.","journal-title":"N Engl J Med"},{"key":"1982_CR2","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard: World Health Organization. 2021. https:\/\/covid19.who.int\/. Accessed 20 Aug 2021."},{"key":"1982_CR3","unstructured":"Laboratory-confirmed COVID-19 associated hospitalizations: COVID-NET: COVID-19 associated hospitalization surveillance network: Centers for Disease Control and Prevention. 2021. https:\/\/gis.cdc.gov\/grasp\/COVIDNet\/COVID19_5.html. Accessed 20 Aug 2021."},{"issue":"1","key":"1982_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/13696998.2021.1886109","volume":"24","author":"M Di Fusco","year":"2021","unstructured":"Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24(1):308\u201317.","journal-title":"J Med Econ"},{"issue":"7","key":"1982_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.vaccine.2020.12.078","volume":"39","author":"M Kohli","year":"2021","unstructured":"Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine. 2021;39(7):1157\u201364.","journal-title":"Vaccine"},{"key":"1982_CR6","unstructured":"FDA. Fact sheet for healthcare providers Emergency Use Authorization (EUA) of baricitinib U.S. Food and Drug Administration. 2021. https:\/\/www.fda.gov\/media\/143823\/download. Accessed 19 Aug 2021."},{"key":"1982_CR7","unstructured":"FDA. Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19. Accessed 20 Aug 2021."},{"issue":"9","key":"1982_CR8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2020","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020;384(9):795\u2013807.","journal-title":"N Engl J Med"},{"key":"1982_CR9","unstructured":"Whittington MD, Campbell J. Alternative pricing models for remdesivir and other potential treatments for COVID-19. June 24 ICER; 2020. https:\/\/icer.org\/news-insights\/press-releases\/updated_icer-covid_models_june_24\/. Accessed 29 April 2021."},{"key":"1982_CR10","unstructured":"Campbell JD, Whittington MD, Rind DM, Pearson SD. Alternative pricing models for remdesivir and other potential treatments for COVID-19; updated report. Institute for Clinical and Economic Review. 2020. http:\/\/icer.org\/wp-content\/uploads\/2020\/11\/ICER-COVID_Updated_Report_11102020.pdf. Accessed 10 Nov 2020."},{"issue":"19","key":"1982_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 \u2014 final report. N Engl J Med. 2020;383(19):1813\u201326.","journal-title":"N Engl J Med"},{"issue":"11","key":"1982_CR12","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048\u201357.","journal-title":"JAMA"},{"issue":"8","key":"1982_CR13","first-page":"693","volume":"384","author":"P Horby","year":"2020","unstructured":"Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2020;384(8):693\u2013704.","journal-title":"N Engl J Med."},{"key":"1982_CR14","unstructured":"Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19 \u2013interim WHO SOLIDARITY trial results. medRxiv. 2020:2020.10.15.20209817."},{"issue":"2","key":"1982_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1524-4733.1998.120131.x","volume":"1","author":"MT Halpern","year":"1998","unstructured":"Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value Health. 1998;1(2):131\u201347.","journal-title":"Value Health"},{"issue":"4","key":"1982_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1089\/met.2008.0070","volume":"7","author":"DM Boudreau","year":"2009","unstructured":"Boudreau DM, Malone DC, Raebel MA, et al. Health care utilization and costs by metabolic syndrome risk factors. Metab Syndr Relat Disord. 2009;7(4):305\u201314.","journal-title":"Metab Syndr Relat Disord"},{"issue":"2","key":"1982_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/ijo.2011.209","volume":"36","author":"ML Vetter","year":"2012","unstructured":"Vetter ML, Wadden TA, Lavenberg J, et al. Erratum: Relation of health-related quality of life to metabolic syndrome, obesity, depression, and comorbid illness. Int J Obes. 2012;36(2):325\u20136.","journal-title":"Int J Obes"},{"issue":"7","key":"1982_CR18","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2337\/diacare.28.7.1769","volume":"28","author":"ES Ford","year":"2005","unstructured":"Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769\u201378.","journal-title":"Diabetes Care"},{"key":"1982_CR19","unstructured":"Premier Applied Sciences\u00ae. Premier healthcare database white paper: data that informs and performs. 2020. https:\/\/learn.premierinc.com\/white-papers\/premierhealthcaredatabase. Accessed 20 Aug 2021."},{"key":"1982_CR20","unstructured":"Data on file. A multicenter, adaptive, randomized blinded controlled study of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults. ACTT-2: Baricitinib\/Remdesivir vs Remdesivir. Final Integrated Clinical\/Statistical Report. 2020."},{"key":"1982_CR21","unstructured":"O\u2019Day D. An open letter from Daniel O\u2019Day, Chairman & CEO, Gilead Sciences. Gilead Sciences. 2020. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/6\/an-open-letter-from-daniel-oday-chairman--ceo-gilead-sciences. Accessed 27 Apr 2021."},{"key":"1982_CR22","unstructured":"Olumiant Price Information 2020. http:\/\/www.lillypricinginfo.com\/olumiant. Accessed 27 Apr 2021."},{"key":"1982_CR23","unstructured":"Labor Force Statistics from the Current Population Survey: Bureau of Labor Statistics. 2021. https:\/\/data.bls.gov\/PDQWeb\/ln. Accessed 26 June 2021."},{"key":"1982_CR24","unstructured":"Garfield RRR, Guth M, Orgera K, Hinton E, Neuman T. Work among medicaid adults: implications of economic downturn and work requirements. Kaiser Family Foundation. 2021. https:\/\/www.kff.org\/report-section\/work-among-medicaid-adults-implications-of-economic-downturn-and-work-requirements-issue-brief\/. Accessed 20 Aug 2021."},{"key":"1982_CR25","unstructured":"Employer Costs for Employee Compensation. Series ID: CMU1010000000000D (C). All civilian total compensation for all occupations; cost per hour worked, 2010 to 2020: Bureau of Labor Statistics. 2021. https:\/\/www.bls.gov\/data\/. Accessed 20 Aug 2021."},{"issue":"4","key":"1982_CR26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006;26(4):410\u201320.","journal-title":"Med Decis Mak"},{"issue":"1","key":"1982_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-019-1081-5","volume":"17","author":"F Barbut","year":"2019","unstructured":"Barbut F, Galperine T, Vanhems P, et al. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes. 2019;17(1):6.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"1982_CR28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0021-9681(78)90072-3","volume":"31","author":"DL Sackett","year":"1978","unstructured":"Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis. 1978;31(11):697\u2013704.","journal-title":"J Chronic Dis"},{"issue":"10","key":"1982_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"key":"1982_CR30","unstructured":"2020\u20132023 Value Assessment Framework. Institute for Clinical and Economic Review. 2020. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf. Accessed 29 Apr 2021."},{"key":"1982_CR31","unstructured":"Social Security Actuarial Life Table. Period Life Table, 2017. https:\/\/www.ssa.gov\/oact\/HistEst\/PerLifeTables\/2017\/PerLifeTables2017.html. Accessed 26 June 2021."},{"key":"1982_CR32","unstructured":"Sarah K, Emond SDP. Alternative policies for pricing novel vaccines and drug therapies for COVID-19. 2020 July 1."},{"key":"1982_CR33","doi-asserted-by":"crossref","unstructured":"ICER update to pricing models of remdesivir for COVID-19. PharmacoEcon Outcomes News. 2020;857(1):2.","DOI":"10.1007\/s40274-020-6939-6"},{"issue":"17","key":"1982_CR34","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.2020.19719","volume":"324","author":"C del Rio","year":"2020","unstructured":"del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324(17):1723\u20134.","journal-title":"JAMA"},{"issue":"8","key":"1982_CR35","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-020-0952-y","volume":"26","author":"IF Miller","year":"2020","unstructured":"Miller IF, Becker AD, Grenfell BT, Metcalf CJE. Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26(8):1212\u20137.","journal-title":"Nat Med"},{"issue":"4","key":"1982_CR36","doi-asserted-by":"publisher","first-page":"e241485","DOI":"10.1136\/bcr-2020-241485","volume":"14","author":"P Taribagil","year":"2021","unstructured":"Taribagil P, Creer D, Tahir H. \u2018Long COVID\u2019 syndrome. BMJ Case Rep. 2021;14(4):e241485.","journal-title":"BMJ Case Rep"},{"key":"1982_CR37","unstructured":"FDA. Fact sheet for healthcare providers: emergency use authorization for Actemra\u00ae (Tocilizumab) U.S. Food and Drug Administration; 2021. https:\/\/www.fda.gov\/media\/150321\/download. Accessed 19 Aug 2021."},{"issue":"4","key":"1982_CR38","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s12325-021-01654-5","volume":"38","author":"D Sheinson","year":"2021","unstructured":"Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021;38(4):1811\u201331. https:\/\/doi.org\/10.1007\/s12325-021-01654-5.","journal-title":"Adv Ther."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01982-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T08:44:56Z","timestamp":1643359496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01982-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1982"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01982-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}